Jerry Martin
Jerry Martin is Senior Vice President and Global Technical Director, Biopharmaceuticals at PALL Life Sciences.
Articles
Reducing the risk of microbial contamination
February 1st 2010Maintaining asepsis and sterility is the primary challenge to implementing aseptic techniques and sterile processes in biopharmaceutical manufacture. Efforts to reduce the risk of microbial contamination of aseptically filled biotech products beyond their already low level represent engineering challenges, that don?t really compliment the progress in biotech R&D.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: August 21st 2024 | Updated: December 26th 2024
Pharmaceutical Technology Editorial Advisory Board
Published: November 25th 2024 | Updated: December 26th 2024
Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics
Published: December 20th 2024 | Updated: December 26th 2024
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Published: February 23rd 2024 | Updated: December 26th 2024
Europa Perspectives: Helping to Navigate the Regulatory System
